Newbury Pharmaceuticals is strengthening its portfolio and strategic focus
Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with additional seven (7) oncology products; Nintedanib, Palbociclib, Pomalidomide, Nilotinib, Enzalutamide, Lenvatinib, Bosutinib.
“The products are a terrific supplement to the existing high-value product portfolio and we are proud to strengthen our commitment within oncology”, says Mr. Lars Minor, CEO of Newbury.
Newbury currently has ten (10) products within oncology and is providing treatment options for both solid and hematological malignancies (e.g. breast cancer, myeloma, leukemia, prostate cancer, NSCLC and thyroid cancer).
Regulatory filling will take place during the next few years, and we aim to be among the first to launch many of these medicines in Scandinavia where the total annual value of this market is estimated to be 400 MEUR according to DLMI Nordic Pharma Insights.
”Newbury is a start-up with high ambitions and we are rapidly growing our portfolio within our focus areas of oncology, rare diseases and neurology. We want to be known to make a difference within these therapeutic areas”, says Karl Karlsson, Founder & Chairman.
